Abstract
C-reactive protein (CRP), a representative inflammatory marker, could serve as a biomarker in renal cell carcinoma because CRP is an important prognostic factor. However, its detailed mechanism remains unknown. This study showed that higher CRP levels correlated with the tumor immune microenvironment, which leads to a worse prognosis. These findings can help to clarify the underlying mechanisms between the presence of systemic inflammatory reaction and prognosis. The aim of this study is to investigate the association between tumor immune microenvironment and CRP in patients with renal cell carcinoma (RCC) to explore the underlying mechanisms between CRP level and prognosis. Immunohistochemical measurement of CD4, CD8, CD163 (M2 macrophages), and Foxp3 (Regulatory T [Treg] cells) was performed in patients with clear-cell RCC (n = 111) treated with radical or partial nephrectomy at our institution. The association between immunohistochemical status and preoperative serum CRP level and cancer-specific survival (CSS) was analyzed. Thirty-three patients (30%) had a high CRP level (≥ 5.0 mg/L), and the CSS rate was significantly worse among these patients than among the remaining patients (P < .001). In patients with strong infiltra...Continue Reading
Citations
Dec 10, 2019·Bioscience Reports·Jian ZhengWeichun Guo
Oct 24, 2019·PloS One·Wei Zhou, Guang-Lin Zhang
Sep 8, 2019·Journal of Cancer Research and Clinical Oncology·Amir-Reza AbolhassaniLucie Heinzerling
Oct 6, 2020·Frontiers in Immunology·Zeyu WangQuan Cheng
Dec 4, 2019·Frontiers in Oncology·Daniel MartinClaus Rödel
Apr 23, 2020·Journal of Translational Medicine·Ulf GunnarssonCaj Haglund
Jun 26, 2020·International Journal of Clinical Practice·Hikmet AkkizAnil Delik
Jan 25, 2021·Urologic Oncology·Eduard RousselBenoit Beuselinck
Dec 16, 2020·Journal of Experimental & Clinical Cancer Research : CR·Xiao-Hui JiaHui Guo
Feb 13, 2021·Cancers·Stepan M EsagianPavlos Msaouel
Dec 10, 2020·International Journal of Molecular Sciences·Victoria S ArmstrongOliver F Bathe
Nov 20, 2020·Scientific Reports·Kazuyuki NumakuraTomonori Habuchi
Feb 27, 2021·PloS One·Nagahiro TokuyamaMasahiro Tsuda
Feb 20, 2021·Journal for Immunotherapy of Cancer·Shohei FukudaYasuhisa Fujii
Mar 16, 2021·IJU Case Reports·Akihito OkazakiTakao Kamai
Mar 29, 2021·Clinical Genitourinary Cancer·Sunil H PatelViraj A Master
Jul 21, 2021·BMC Cancer·Yingkai HongPeilin Shen